▽The New England Journal of Medicine: Research & Review Articles on Diseases & Clinical Practice ●04/03 13:13 Nov 27, 2024CMETwice-Yearly Lenacapavir for HIV PreventionC.F. Kelley and OthersIn this phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background incidence and the incidence with emtricitabine–tenofovir disoproxil fumarate.Editorial Working at Cross-PURPOSEs to Ending HIVApr 02, 2025Upadacitinib for Giant-Cell ArteritisD. Blockmans and O